■系统性红斑狼疮(SLE),一种广泛的自身免疫性疾病,损害病毒抗性并改变呼吸道病毒疫苗后的免疫反应。本研究旨在评估呼吸道病毒疫苗接种后SLE患者的免疫反应水平和安全性。
■广泛的搜索,直到2024年3月1日,都是使用PubMed进行的,EMBASE,科克伦图书馆结果,包括血清转化率(SCR),抗体和IgG滴度,中和抗体,抗尖峰抗体,抗受体结合域(RBD)IgG,和不良事件,被评估了。
■16篇文章,包括25项观察性研究,包括在内。SLE患者表现出较低的SCR(OR=0.42,95CI:0.26至0.69),抗体滴度(SMD=-2.84,95CI:-3.36至-1.61),和中和抗体(OR=0.27,95CI:0.13至0.56)与健康人群呼吸道后病毒疫苗相比。值得注意的是,抗RBDIgG的差异无统计学意义(OR=1.75,95CI:0.10至29.42),IgG滴度(SMD=-2.54,95CI:-5.57至-0.49),抗刺突抗体(OR=0.35,95CI:0.08至1.53),注射部位不适(OR=1.03,95CI:0.52至2.06),疲劳(OR=1.23,95CI:0.74至2.03),发烧(OR=1.02,95CI:0.64至1.63),局部反应(OR=0.69,95CI:0.37至1.30),全身反应(OR=1.00,95CI:0.59至1.69),过敏反应(OR=5.11,95CI:0.24至107.10),自我报告的疫苗接种相关不良事件(OR=1.61,95CI:0.56至4.63),接种疫苗后疾病发作(OR=1.00,95CI:0.14至7.28)。
尽管与健康人群相比,2019年冠状病毒病(COVID-19)和流感疫苗后的SLE患者的免疫反应和宿主保护降低,安全性具有可比性。因此,建议SLE患者接种COVID-19和流感病毒疫苗以增强其耐药性.
UNASSIGNED: Systemic lupus erythematosus (SLE), an extensive autoimmune disorder, compromises viral resistance and alters immune responses post respiratory virus vaccines. This study aims to assess immune response levels and safety in SLE patients following respiratory virus vaccines.
UNASSIGNED: Extensive searches, until 1 March 2024, were conducted using PubMed, EMBASE, and Cochrane Library. Outcomes, encompassing seroconversion rate (SCR), antibody and IgG titers, neutralizing antibodies, anti-spike antibodies, anti-receptor binding domain (RBD) IgG, and adverse events, were appraised.
UNASSIGNED: Sixteen articles, comprising 25 observational studies, were included. SLE patients exhibited lower SCR (OR = 0.42, 95%CI: 0.26 to 0.69), antibody titers (SMD=-2.84, 95%CI: -3.36 to -1.61), and neutralizing antibodies (OR = 0.27, 95%CI: 0.13 to 0.56) compared to the healthy population post respiratory virus vaccines. Notably, differences were statistically insignificant for anti-RBD IgG (OR = 1.75, 95%CI: 0.10 to 29.42), IgG titers (SMD=-2.54, 95%CI: -5.57 to -0.49), anti-spike antibodies (OR = 0.35, 95%CI: 0.08 to 1.53), injection site discomfort (OR = 1.03, 95%CI: 0.52 to 2.06), fatigue (OR = 1.23, 95%CI: 0.74 to 2.03), fever (OR = 1.02, 95%CI: 0.64 to 1.63), localized reactions (OR = 0.69, 95%CI: 0.37 to 1.30), systemic reactions (OR = 1.00, 95%CI: 0.59 to 1.69), allergic reactions (OR = 5.11, 95%CI: 0.24 to 107.10), self-reported vaccination-related adverse events (OR = 1.61, 95%CI: 0.56 to 4.63), and disease flares after vaccination (OR = 1.00, 95%CI: 0.14 to 7.28).
UNASSIGNED: Despite the reduced immune response and host protection in SLE patients post-Corona Virus Disease 2019 (COVID-19) and influenza vaccines compared to the healthy population, safety profiles are comparable. Therefore, it is recommended that SLE patients receive COVID-19 and influenza viral vaccines to fortify their resistance.